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In order to directly demonstrate the roles of CD8+ T lymphocytes in non-human 31 
primates, in vivo depletion of the CD8+ T cells by administration of a CD8-specific 32 
monoclonal antibody (mAb) is one of the crucial techniques. Recently, the common 33 
marmoset (Callithrix jacchus), which is classified as a New World monkey, has been 34 
shown useful as an experimental animal model for various human diseases such as 35 
multiple sclerosis, Parkinson’s disease and a number of infectious diseases. Here we 36 
show that an anti-marmoset CD8 mAb 6F10, which we have recently established, 37 
efficiently depletes the marmoset CD8+ T lymphocytes in vivo, i.e., the administration 38 
of 6F10 induces drastic and specific reduction in the ratio of the CD8+ T cell subset for 39 
at least three weeks or longer. Our finding will help understand the pivotal role of 40 





1. Introduction 45 
 46 
The use of non-human primates as experimental animal models is highly effective for 47 
research on human diseases. Non-human primates and humans share comparable 48 
immune systems as compared with mice and are suitable for the evaluation of innate 49 
and adaptive immune responses against several viruses[1,2]. On the other hand, there 50 
are also several issues with chimpanzees and macaques. The most prevalent being that 51 
the use of the chimpanzee is limited by ethical and financial restrictions [3-6].  52 
      A New World monkey, the common marmoset (Callithrix jacchus) has several 53 
advantages as an experimental animal model. The small size of the marmoset makes it 54 
easier to handle and reduces maintenance costs [7]. Recently, it has been reported that 55 
the marmoset model is a very useful tool in investigating multiple sclerosis (MS), 56 
rheumatoid arthritis (RA) and Parkinson’s disease [8-10]. Moreover, the marmoset has 57 
an immune system similar to that of humans and is suitable for the evaluation of innate 58 
and adaptive immune responses against several viruses which efficiently replicate in 59 
the marmoset [11-14].  60 
      CD8+ T lymphocytes are a vital component of the adaptive immune response 61 
and are crucial to the control and clearance of intracellular pathogens. These cells play 62 
critical roles in purging acute infections, limiting persistent infections, and conferring 63 
life-long protective immunity. In order to clarify the pivotal role of CD8+ T cells in a 64 
variety of non-human primate models for human diseases, in vivo depletion of CD8+ T 65 
cells by administration of a CD8-specific monoclonal antibody (mAb) is a 66 
straightforward technique, although it has been established in Old World monkeys but 67 
not in New World monkeys [15-21].  68 
We recently established a novel mAb 6F10 specific for common marmoset 69 
 4 
CD8 [7]. In this study, we demonstrated for the first time in New World monkeys that 70 
the administration of the 6F10 mAb efficiently depleted CD8+ T lymphocytes in 71 
marmosets.   72 
 5 
2. Materials and Methods 73 
2.1. Animals 74 
All animal studies were conducted in accordance with the protocols of 75 
experimental procedures that were approved by the Animal Welfare and Animal Care 76 
Committee of the Primate Research Institute of Kyoto University, Inuyama, Japan. A 77 
total of three marmosets, weighing 357-457 g, were used. Common marmosets were 78 
caged individually at 27±2 °C in 50±10% humidity with a 12h light-dark cycle 79 
(lighting from 7:00 to 19:00) in our facility. All animals were fed twice a day with a 80 
standard marmoset diet supplemented with fruit and mealworm. Water was given ad 81 
libitum. 82 
2.2. Flow cytometry 83 
 Flow cytometry was performed as previously described with a slight modification 84 
[22]. A previously established mouse anti-marmoset CD8 mAb named 6F10 was used 85 
[7]. The 6F10 mAb was conjugated with allophycocyanin (APC) and by Zenon Mouse 86 
IgG labeling Kit (Molecular Probes) according to the manufacturer’s instruction. Fifty 87 
microliters of whole blood from marmosets was stained with combinations of 88 
fluorescence-conjugated mAb: APC-Cy7-conjugated anti-CD3 (SP34-2: Becton 89 
Dickinson), PerCP-Cy5.5-conjugated anti-CD4 (L200: BD Pharmingen), PE-conjugated 90 
anti-CD8 (CLB-T8/4, 4H8 (CLB hereafter): Sanquin; RPA-T8 (T8 hereafter): Becton 91 
Dickinson) and FITC-conjugated anti-CD20 (H299: BECKMAN COULTER). Then, 92 
erythrocytes were lysed with FACS lysing solution (Becton Dickinson). After washing 93 
with a sample buffer containing phosphate-buffered saline (PBS) and 1% fetal calf 94 
serum (FCS), the labeled cells were resuspended in a fix buffer containing PBS and 1% 95 
formaldehyde. The expression of the immunolabeled molecules on the lymphocytes was 96 
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analyzed with a FACSCanto II flow cytometer (Becton Dickinson). The data analysis 97 
was conducted using FlowJo software (Treestar, Inc.).  98 
2.3. In vitro binding competition of anti-CD8 mAbs 99 
 Fifty microliters of whole blood from marmosets was treated with increasing 100 
amounts (1, 10, 100 ng) of the 6F10 mAb on ice for 30 min. After washing with the 101 
sample buffer, the cells were stained with fluorescence-conjugated mAbs against CD3, 102 
CD4, and CD8 on ice for 30 min. Then, erythrocytes were lysed with FACS lysing 103 
solution (Becton Dickinson). After washing with the sample buffer, the labeled cells 104 
were resuspended in the fix buffer. The fluorescence intensity of the cells were analyzed 105 
at is as described above. 106 
2.4. In vivo depletion of CD8+ T lymphocytes 107 
In vivo depletion of the marmoset CD8+ T lymphocytes was performed as 108 
previously described [19]. Briefly, the 6F10 or a control mAb (MOPC-21) was 109 
administrated subcutaneously to the subject at 10 mg/kg (body weight) followed by 110 
intravenous administration at 5 mg/kg in the saphenous vein at a rate of 20 ml/h using 111 
a syringe pump on days 3, 7, 10 after the primary administration. The kinetics for the 112 
percentages of CD8+ and CD4+ cells in a CD3+ T cell subset as well as the percentages 113 
of CD20+ B cells and CD3-CD20- cells in the total lymphocytes of each marmoset were 114 
periodically monitored during the observation period as indicated. 115 
2.5. Statistical analyses 116 
Statistical analyses of lymphocyte ratios were performed using 117 
Student’s t-test and single-factor ANOVA, followed by Fisher’s protected 118 
least-significant difference post hoc test by using StatView software (SAS 119 
Institute, NC, USA).   120 
 7 
3. Results 121 
 122 
3.1. Lymphocyte subsets in marmosets  123 
We previously demonstrated that the 6F10 mAb specifically detected CD8+ 124 
T lymphocytes in marmosets by using flow cytometry as well as immunohistochemical 125 
and Western blot analyses [7]. Basic information regarding CD4/CD8 naïve and 126 
central/effector memory T cells and NK/NKT cells in marmosets was available from 127 
our recent report [13]. We compared the immunoreactivity of the 6F10 mAb with other 128 
commercially available CD8 mAbs in lymphocyte subsets of marmosets (Fig. 1). The 129 
gating strategy for profiling CD4+ and CD8+ T cells was shown in Figure 1. The 130 
percentage of CD8+ T cells in a CD3+ T cell subset as detected by 6F10, CLB or T8 131 
anti-CD8 mAb was comparable (23.5%, 23.2% and 22.9%, respectively). Notably, the 132 
6F10 mAb poorly cross-reacted with tamarin and rhesus macaque CD8+ T cells while 133 
CLB and T8 mAbs did with both (data not shown). It is reasonable that the 6F10 mAb 134 
showed selected specificity to the marmoset CD8, considering that it was established 135 
by immunization with marmoset lymphocytes [7]. 136 
 137 
3.2. In vitro binding competition of anti-CD8 antibodies in CD8+ T cells of 138 
marmosets 139 
We initially treated the marmoset lymphocytes with increasing amounts of 140 
APC-conjugated 6F10 together with fluorescence-labeled mAbs to CD3 and CD4. It 141 
was found that fluorescence intensity for APC on a CD3+ T cell subset was saturated 142 
by 10 ng or more of 6F10 mAb (Fig.2A). We then sought to define whether the 143 
binding epitope of 6F10 mAb in the marmoset CD8 molecule was overlapped with the 144 
epitopes of T8 and CLB mAbs by a competition assay. It was found that fluorescence 145 
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intensity in the CD3+ T cell subset treated with the labeled CLB mAb was drastically 146 
reduced by the pretreatment of 10 or 100 ng 6F10 (Fig. 2B, C). On the other hand, the 147 
6F10 pretreatment scarcely influenced fluorescence intensity in the cells that reacted 148 
with the labeled T8 mAb, irrespective of the amounts of 6F10 (Fig. 2B, C). These 149 
results indicated that 6F10 competitively inhibited binding of CLB but not T8 mAbs to 150 
CD8, suggesting that the binding epitope for 6F10 was overlapped with that of CLB 151 
and was sterically apart from that of T8. In addition, T8 was likely to exhibit greater 152 
affinity than CLB to marmoset CD8 (Fig 2B).    153 
 154 
3.3. In vivo depletion of CD8+ T cells using an anti-marmoset CD8 mAb 155 
We finally examined whether the administration of the 6F10 mAb could influence 156 
CD8+ T lymphocytes in vivo. Three marmosets were subcutaneously administrated at 157 
10 mg/kg followed by intravenous administration at 5 mg/kg on days 3, 7, 10 after the 158 
primary administration. The mAb-treated marmosets did not develop any clinical and 159 
hematological signs (data not shown). In order to detect CD8+ T lymphocytes in the 160 
6F10-treated marmosets, we employed T8 mAb, which was found to react with CD8 161 
molecule in the presence of 6F10 as shown in Fig. 2. It was found that at 10 days after 162 
the mAb administration the CD8+ T cells were almost completely depleted, followed 163 
by gradual recovery to a half of the initial levels at around 4-7 weeks later (Fig. 3). It is 164 
noteworthy that the treatment relatively increased in the proportion of CD4+ T cells in 165 
compensation for the depletion of CD8+ T cells, while the ratios of CD20+ B cells and 166 
CD3-CD20- cells were scarcely affected (Fig. 4). In addition, administration of a 167 
control antibody (MOPC-21) did not affect any lymphocyte subsets (data not shown). 168 
These results demonstrated that the 6F10 mAb was able to specifically deplete CD8+ T 169 
cells in marmosets. 170 
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4. Discussion 171 
In this study, we attempted to establish a technical basis for the study of CD8+ 172 
T cells in marmosets. We assessed the effect of a 6F10 mAb administration in vivo and 173 
found that CD8+ T cells were efficiently depleted in the blood of the treated monkeys 174 
for at least three weeks or longer and that in compensation for the depletion proportion 175 
of CD4+ T cells were relatively increased without obvious influence on other 176 
lymphocyte subsets such as CD20+ B cells and CD3-CD20- cells. This is the first report 177 
showing the establishment of new methodology to deplete common marmoset CD8+ T 178 
lymphocytes in vivo. Since demand for marmosets as non-human primate models for a 179 
variety of inflammatory and autoimmune diseases as well as infectious diseases has 180 
been increasing, our findings will provide new techniques to scientists who are eager to 181 
examine the pivotal role of CD8+ T lymphocytes in vivo in the onset of the human 182 
diseases. 183 
      We previously sought to examine the dynamics of cellular immune responses in 184 
the acute phase of dengue virus (DENV) infection in a novel marmoset model that we 185 
recently developed [12]. We found that the DENV infection in marmosets greatly 186 
induced early immune responses of CD4/CD8 central memory T cells, suggesting that 187 
the cellular immunity may be associated with the control of primary DENV infection 188 
[13]. Considering this, the present techniques to deplete CD8+ T cells in vivo will 189 
provide a useful tool to further elucidate the functional role of CD8+ T cells in the acute 190 
DENV infection.  191 
      Common marmosets are suitable for detailed observations of the movement of 192 
the extremities and cognitive functions, which approximate those of humans. Therefore, 193 
marmosets are highly useful as models of neurological diseases such as Parkinson’s, 194 
MS and RA. Importantly, the marmoset models for analyzing Parkinson’s disease and 195 
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autoimmune diseases such as MS and RA have already been developed [8-10,23]. CD8+ 196 
T cells have been implicated in the pathogenesis of autoimmune disorders including 197 
diseases of the central nervous system such as MS, encephalomyelitis and diabetes 198 
mellitus [24-26]. MS is an immune-mediated disease of the central nervous system 199 
leading to demyelination and axonal/neuronal loss. Accumulating evidence points to a 200 
key role for CD8+ T cells in the disease; histopathological analyses and compelling 201 
observations from animal models indicate that cytotoxic CD8+ T cells target neural cell 202 
populations with the potential of causing lesions consistent with MS [27]. RA is a 203 
systemic and chronic autoimmune disease characterized mainly by synovial 204 
inflammation leading to joint destruction and disability with a huge impact upon the 205 
quality of life and life expectancy. Several studies have demonstrated that CD8+ T cells 206 
in RA have powerful cytotoxic ability and therefore exhibit the potential to enhance the 207 
disease [28]. Thus, our in vivo CD8 depletion technics will be valuable in further 208 
examining the role of CD8+ T cells in these autoimmune diseases in the marmoset 209 
models.             210 
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Figure legends 220 
 221 
Figure 1. Flow cytometric analyses of CD3, CD4 and CD8 expression on lymphocytes 222 
in marmosets. Fifty microliters of whole blood specimens from marmosets were 223 
stained with APC-Cy7-conjugated anti-CD3, PerCP-Cy5.5-conjugated anti-CD4 and 224 
APC-conjugated 6F10 mAbs or PE-conjugated CD8 (CLB or T8) mAb. Then, 225 
erythrocytes were lysed and the stained cells were resuspended in the fix buffer. 226 
Representative results in a marmoset are shown. The G1 lymphocyte population was 227 
selected (left top panel) and a CD3+ T cell subset was gated (right top panel). 228 
Fluorescence intensity for CD4 and CD8 in the T cell subset was depicted (lower 229 
panels).  230 
 231 
Figure 2. Binding competition among anti-CD8 mAbs in marmoset CD8+ T cells. (A) 232 
Fifty microliters of whole blood specimens from marmosets were stained with 233 
APC-Cy7-conjugated CD3 and PerCP-Cy5.5-conjugated CD4 mAbs and increasing 234 
amounts (1, 10, 100 ng) of APC-conjugated 6F10 mAb. Then, erythrocytes were lysed 235 
and the stained cells were resuspended in the fix buffer. The fluorescence intensity for 236 
CD4+ and CD8+ cells in a CD3+ T cell subset was shown. (B, C) Fifty microliters of 237 
whole blood specimens were pretreated with increasing amounts (1, 10, 100 ng) of 6F10 238 
mAb, followed by staining with fluorescence-conjugated mAbs against CD3, CD4, and 239 
CD8 (CLB or T8). Fluorescence intensity of CD4+ and CD8+ cells in a CD3+ T cell 240 
subset was shown (B) and the geometric mean fluorescence of CD8+ T cells labeled by 241 
the CLB or T8 mAbs was indicated. We analyzed statistically whether geometric means 242 
were different in each antibody by using StatView software. 243 
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Figure 3. In vivo depletion of CD8+ T cells by administration of a marmoset anti-CD8 244 
mAb 6F10. Periodical kinetics for the fluorescence intensity of CD4+ and CD8+ cells 245 
in a CD3+ T cell subset of Cj175 administered subcutaneously with 10 mg/kg of the 246 
6F10 mAb, followed by 5 mg/kg administration intravenously at days 3, 7, and 10 247 
were shown.  248 
 249 
Figure 4. The kinetics for the ratios of CD8+ cells (A) and CD4+ cells (B) in a CD3+ T 250 
cell subset as well as CD20+ B cells (C) and CD3-CD20- cells (D) in total lymphocytes 251 
of each marmoset after the administration of the 6F10 mAb were shown. 252 
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References 253 
[1] Meuleman P, Leroux-Roels G. HCV animal models: a journey of more than 30 254 
years. Viruses 2009;1:222-240. 255 
[2] Zompi S, Harris E. Animal models of dengue virus infection. Viruses 256 
2012;4:62-82. 257 
[3] Gagneux P, Moore JJ, Varki A. The ethics of research on great apes. Nature 258 
2005;437:27-29. 259 
[4] Knight A. The beginning of the end for chimpanzee experiments? Philos Ethics 260 
Humanit Med 2008;3:16. 261 
[5] Morimura N, Idani G, Matsuzawa T. The first chimpanzee sanctuary in Japan: 262 
an attempt to care for the "surplus" of biomedical research. Am J Primatol 263 
2011;73:226-232. 264 
[6] Brass V, Moradpour D, Blum HE. Hepatitis C virus infection: in vivo and in 265 
vitro models. J Viral Hepat 2007;14 Suppl 1:64-67. 266 
[7] Ito R, Maekawa S, Kawai K, Suemizu H, Suzuki S, Ishii H, et al. Novel 267 
monoclonal antibodies recognizing different subsets of lymphocytes from the 268 
common marmoset (Callithrix jacchus). Immunol Lett 2008;121:116-122. 269 
[8] Ando K, Obayashi S, Nagai Y, Oh-Nishi A, Minamimoto T, Higuchi M, et al. 270 
PET analysis of dopaminergic neurodegeneration in relation to immobility in 271 
the MPTP-treated common marmoset, a model for Parkinson's disease. PLoS 272 
One 2012;7:e46371. 273 
[9] Jagessar SA, Gran B, Heijmans N, Bauer J, Laman JD, t Hart BA, et al. 274 
Discrepant effects of human interferon-gamma on clinical and immunological 275 
disease parameters in a novel marmoset model for multiple sclerosis. J 276 
Neuroimmune Pharmacol 2012;7:253-265. 277 
[10] Petersen F, Yu X. A novel preclinical model for rheumatoid arthritis research. 278 
Arthritis Res Ther 2010;12:148. 279 
[11] Woollard DJ, Haqshenas G, Dong X, Pratt BF, Kent SJ, Gowans EJ. 280 
Virus-specific T-cell immunity correlates with control of GB virus B infection 281 
in marmosets. J Virol 2008;82:3054-3060. 282 
[12] Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, et al. 283 
Common marmoset (Callithrix jacchus) as a primate model of dengue virus 284 
infection: development of high levels of viraemia and demonstration of 285 
protective immunity. J Gen Virol 2011;92:2272-2280. 286 
[13] Yoshida T, Omatsu T, Saito A, Katakai Y, Iwasaki Y, Kurosawa T, et al. 287 
Dynamics of cellular immune responses in the acute phase of dengue virus 288 
 15 
infection. Arch Virol 2013;158:1209-1220. 289 
[14] Omatsu T, Moi ML, Takasaki T, Nakamura S, Katakai Y, Tajima S, et al. 290 
Changes in hematological and serum biochemical parameters in common 291 
marmosets (Callithrix jacchus) after inoculation with dengue virus. J Med 292 
Primatol 2012;41:289-296. 293 
[15] Barry AP, Silvestri G, Safrit JT, Sumpter B, Kozyr N, McClure HM, et al. 294 
Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with 295 
simian immunodeficiency virus reveals limited role for immune control of virus 296 
replication in a natural host species. J Immunol 2007;178:8002-8012. 297 
[16] Castro BA, Homsy J, Lennette E, Murthy KK, Eichberg JW, Levy JA. HIV-1 298 
expression in chimpanzees can be activated by CD8+ cell depletion or CMV 299 
infection. Clin Immunol Immunopathol 1992;65:227-233. 300 
[17] Ramalingam RK, Meyer-Olson D, Shoukry NH, Bowen DG, Walker CM, 301 
Kalams SA. Kinetic analysis by real-time PCR of hepatitis C virus 302 
(HCV)-specific T cells in peripheral blood and liver after challenge with HCV. 303 
J Virol 2008;82:10487-10492. 304 
[18] Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et 305 
al. Memory CD8+ T cells are required for protection from persistent hepatitis C 306 
virus infection. J Exp Med 2003;197:1645-1655. 307 
[19] Saito A, Nomaguchi M, Iijima S, Kuroishi A, Yoshida T, Lee YJ, et al. 308 
Improved capacity of a monkey-tropic HIV-1 derivative to replicate in 309 
cynomolgus monkeys with minimal modifications. Microbes Infect 310 
2011;13:58-64. 311 
[20] Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic 312 
rise in plasma viremia after CD8(+) T cell depletion in simian 313 
immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998. 314 
[21] Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, et al. Effects of 315 
in vivo CD8(+) T cell depletion on virus replication in rhesus macaques 316 
immunized with a live, attenuated simian immunodeficiency virus vaccine. J 317 
Exp Med 2000;191:1921-1931. 318 
[22] Yoshida T, Saito A, Iwasaki Y, Iijima S, Kurosawa T, Katakai Y, et al. 319 
Characterization of natural killer cells in tamarins: a technical basis for studies 320 
of innate immunity. Front Microbiol 2010;1:128. 321 
[23] Jagessar SA, Heijmans N, Bauer J, Blezer EL, Laman JD, Hellings N, et al. 322 
B-cell depletion abrogates T cell-mediated demyelination in an 323 
antibody-nondependent common marmoset experimental autoimmune 324 
encephalomyelitis model. J Neuropathol Exp Neurol 2012;71:716-728. 325 
 16 
[24] Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, et al. 326 
CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. 327 
Brain 2011;134:542-554. 328 
[25] York NR, Mendoza JP, Ortega SB, Benagh A, Tyler AF, Firan M, et al. 329 
Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune 330 
encephalomyelitis. J Autoimmun 2010;35:33-44. 331 
[26] Wang J, Ma Y, Knechtle SJ. Adenovirus-mediated gene transfer into rat cardiac 332 
allografts. Comparison of direct injection and perfusion. Transplantation 333 
1996;61:1726-1729. 334 
[27] Saxena A, Martin-Blondel G, Mars LT, Liblau RS. Role of CD8 T cell subsets 335 
in the pathogenesis of multiple sclerosis. FEBS Lett 2011;585:3758-3763. 336 
[28] Carvalheiro H, da Silva JA, Souto-Carneiro MM. Potential roles for CD8(+) T 337 
cells in rheumatoid arthritis. Autoimmun Rev 2013;12:401-409. 338 
 339 
 340 
Conflict of Interest Statement:  341 
The authors declare that the research was conducted in the absence of any commercial 342 
or financial relationships that could be construed as a potential conflict of interest.  343 
  344 
 17 
  345 
 18 
  346 
 19 
 347 




  351 
 21 
 352 
 353 
